Comparison
CJC-1295 vs Magnesium Glycinate
Side-by-side of CJC-1295 and Magnesium Glycinate. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
CJC-1295
CJC-1295 peptide profile: GHRH analog forms (with-DAC ~7-day half-life, no-DAC Mod GRF 1-29 ~30 min), ipamorelin pairing, recovery use, dosing, side effects.
Magnesium Glycinate
Magnesium glycinate supplement guide: chelated bisglycinate form, 200 to 400 mg dosage, sleep architecture benefits, low GI side effects, glycine co-effect.
Effects at a glance
CJC-1295
- •GHRH analog that binds the GHRH receptor on pituitary somatotrophs to release endogenous GH
- •DAC variant has ~7 day half-life via albumin binding; non-DAC variant ~30 minutes
- •Teichman 2006 trial showed sustained 2 to 10 fold IGF-1 elevation at 60 to 250 mcg/kg DAC dosing
- •Anecdotal protocols pair non-DAC CJC-1295 with Ipamorelin to mimic pulsatile GH release
- •Side effects: water retention, numbness or tingling at injection site, vivid dreams, transient flushing
- •No completed phase III RCTs; research-use-only and not FDA approved
Magnesium Glycinate
- •Shortens sleep onset latency in older adults and in deficient populations supplementing 200 to 400 mg elemental Mg
- •Improves subjective sleep quality scores (PSQI, ISI) modestly versus placebo over 4 to 8 weeks
- •Reduces nocturnal leg cramps and exercise-induced muscle cramping in some controlled trials
- •Lowers self-reported anxiety in mild-to-moderate cases, with smaller effect than first-line pharmacotherapy
- •Glycinate form delivers fewer GI side effects than oxide or citrate at equivalent elemental doses
- •Insufficient as a stand-alone hypertension treatment; small adjunctive blood-pressure reductions only
Side-by-side
| Attribute | CJC-1295 | Magnesium Glycinate |
|---|---|---|
| Category | peptide | supplement |
| Also known as | CJC-1295 DAC, CJC-1295 no-DAC, Mod GRF 1-29, tesamorelin analog | magnesium bisglycinate |
| Half-life (hr) ↗ | 168 | 5 |
| Typical dose (mg) ↗ | 0.1 | 300 |
| Dosing frequency | weekly (DAC); 1-3x daily (non-DAC) | daily (often evening) |
| Routes | subcutaneous | oral |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 3 | - |
| Molecular weight | 3367.83 | - |
| Molecular formula | C152H252N44O42 | - |
| Mechanism | Binds the GHRH receptor on pituitary somatotrophs, stimulating pulsatile growth-hormone release. The DAC modification extends plasma residence by tethering the peptide to serum albumin via a maleimide-cysteine bond. | Magnesium acts as a cofactor for 300+ enzymes and as a voltage-dependent antagonist at NMDA receptors; glycine serves as an inhibitory neurotransmitter and co-agonist at glycine receptors. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA | Dietary supplement |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | OTC supplement |
| Pregnancy | Insufficient data; not recommended | Generally considered acceptable at RDA doses; consult clinician |
| CAS | 446262-90-4 | 14783-68-7 |
| PubChem CID | 91971820 | 84645 |
| Wikidata | Q5012154 | - |
Safety profile
CJC-1295
Common side effects
- injection-site reactions
- water retention
- numbness or tingling at injection site
- vivid dreams
- transient flushing
- head pressure or mild headache
Contraindications
- pregnancy
- active malignancy
- diabetic retinopathy (theoretical)
- history of pituitary tumor
Interactions
- Ipamorelin: synergistic GH release; commonly co-administered in anecdotal protocols(minor)
- insulin: GH-induced insulin resistance can shift glycemic control over weeks(moderate)
- corticosteroids: blunt GH-axis response; reduce expected efficacy(moderate)
Magnesium Glycinate
Common side effects
- mild GI upset at high doses
- loose stools (dose-dependent, less than with oxide/citrate forms)
Contraindications
- severe renal impairment
- myasthenia gravis
- heart block
Interactions
- tetracycline and fluoroquinolone antibiotics: magnesium chelates antibiotic, reducing absorption; separate by 2+ hours(moderate)
- bisphosphonates: reduced absorption of bisphosphonate(moderate)
- potassium-sparing diuretics: possible hypermagnesemia in renal impairment(moderate)
Which Should You Take?
Magnesium Glycinate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. CJC-1295 is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick CJC-1295.
- → If your priority is body composition, pick CJC-1295.
- → If your priority is sleep onset or sleep quality, pick Magnesium Glycinate.
- → If your priority is stress and HPA-axis regulation, pick Magnesium Glycinate.
Edge case: If you want to avoid research-only / gray-market sourcing, Magnesium Glycinate is the more accessible choice.
Default choice: Magnesium Glycinate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for CJC-1295 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between CJC-1295 and Magnesium Glycinate?
CJC-1295 and Magnesium Glycinate differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, CJC-1295 or Magnesium Glycinate?
CJC-1295 half-life is 168 hours; Magnesium Glycinate half-life is 5 hours.
Can you stack CJC-1295 with Magnesium Glycinate?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper